Where to Find Treatment for GM1 Gangliosidosis?

Where to Find Treatment for GM1 Gangliosidosis

Background on the Disease

There is no approved treatment yet, and the search for one is shaped by how the disease works at a cellular level.[1] For causes, subtypes and life expectancy, see our complete guide to GM1 gangliosidosis.

What Is GM1 and Are There Any Treatments Today?

GM1 gangliosidosis is a rare genetic and neurodegenerative disease caused by a deficiency of the enzyme beta-galactosidase. This leads to a toxic buildup of GM1 ganglioside and substrates in the brain and organs.[1]

Currently, there is no approved treatment or cure that stops or reverses the disease.[1] However, we are in a “pivotal era” of research. Today, treatment means a dual approach: Expert Symptom Management and Investigational Research.

Clinical trials have been most successful to date for Type 2 GM1 and more specifically, Type 2b GM1.  This is primarily due to the reduced severity of the juvenile subtype.[2]  At this time, a significant unmet need is treatment of the infantile forms of GM1.[3][4]  Due to the lack of newborn screening and diagnostic odysseys, development of possible treatments for infantile forms of GM1 has been significantly more challenging.

1. Finding Expert Clinical Care

Because GM1 affects multiple systems (neurological, skeletal, and organ health), families should seek care at specialized Lysosomal Storage Disease (LSD) Centers.[1] These centers provide specialized care which includes:

  • Seizure Management: Specialized protocols using anticonvulsants
  • Gastrointestinal Support: Management of feeding difficulties and nutrition.
  • Dietary Approaches: A low-carbohydrate ketogenic diet has been studied in GM1 in combination with miglustat, known as the Syner-G regimen, where it was associated with longer survival in infantile GM1 among children who had a feeding tube.[5][6]
  • Respiratory Care: To maintain respiratory health

Specialized Centers (U.S. & International)

  • UCSF Benioff Children’s Hospital (San Francisco/Oakland): Conducts both natural history studies and clinical trials[7][8] 

  • University of Minnesota (Minneapolis): Conducts both natural history studies and clinical trials[8][9] 
  • National Institutes of Health (NIH): Conducts long-term natural history studies and clinical trials[10][11]

  • Additional International Hubs: Expert centers are located at Great Ormond Street Hospital and Royal Manchester Children’s Hospital in the UK, Hospital de Clínicas de Porto Alegre in Brazil, and SphinCS in Höchheim, Germany[12][13]

2. Investigational Therapies (Clinical Trials)

Gene Therapy (Correcting the Gene)

AAV-based gene therapies deliver a working GLB1 gene to the patient’s cells.[14]

  • Current Status (2026): Clinical trials in AAV gene therapy to date have shown safety and biochemical improvements.[14] The National Human Genome Research Institute is currently conducting a clinical trial in Type 2 patients (NCT03952637).[14][11]  Gemma Biotherapeutics / RareTx is actively advancing the PBGM01 gene therapy program originally developed by Passage Bio. The study (NCT04713475) is not currently open to enrollment.[8]
  • Prenatal gene therapy: A first-in-human Phase 1 trial of in-utero AAV9 GLB1 gene transfer is registered at the University of California San Francisco, sponsored by Dr. Tippi Mackenzie (NCT07479953). As of August 2026 the registry lists it as not yet recruiting, with an estimated start in 2026 and five participants planned.[15]

Substrate Reduction Therapy (Reducing the Waste)

This approach uses oral medication to stop the body from making the “waste” that builds up.

  • Venglustat: Studied in GM1 patients in the secondary basket trial arm for a study by Sanofi.[16]  The trial demonstrated reduction of GM1 ganglioside in cerebrospinal fluid in a small number of trial participants.[16][16]  The primary arm of the trial failed in late-onset Tay-Sachs[16] and the trial overall was shut down.[17][18]  Development of this drug has continued in Fabry disease and Gaucher disease.  A Phase 3 trial in Gaucher disease type 3 (NCT05222906) is active but no longer enrolling, with completion estimated for October 2026.[19] 
  • Nizubaglustat: As of early 2026, this is in Phase 3 clinical trials (the final stage before potential approval). It is being studied at 26 sites across 14 countries.  The GM1 and GM2 study (NCT07082543) has completed enrollment and is closed to new participants.[20]

Enzyme Replacement Therapy (ERT)

Supplying the missing enzyme directly. While ERT is approved for other diseases (like Gaucher), it is still in the research and fundraising stage for GM1, led by organizations like Cure GM1.[1]

3. How to Access These Opportunities

  1. Learn about the GM1 Matrix: This is a global patient registry which helps families affected by GM1 share data that can guide research, improve diagnosis, and make the GM1 community more visible.
  2. Search ClinicalTrials.gov: Use search terms like “GM1 gangliosidosis” or “GLB1” to see every active study worldwide.
  3. Contact Cure GM1 Foundation: They act as the primary bridge between families and the biotech companies running these trials.
  4. Read our guide: GM1 Clinical Trials Guide.

Cure GM1 Resources

FAQs

Which GM1 type has the most treatment options?

Currently, the trials are focused mainly on Type-2 juvenile with the highest number of active clinical trials.  The NIH gene therapy clinical trial does screen Type-2 late-infantile candidates, but late diagnoses tend to prevent meeting the trial inclusion criteria.  There are currently no clinical trials enrolling for  Type-1 (Infantile).

Can Gene Therapy reverse damage that has already occurred?

Generally, no. Most current therapies aim to stop or slow further progression. This is why early diagnosis is so critical.

Does insurance cover clinical trial costs?

Most clinical trial sponsors cover the cost of the investigational drug and study-related exams.  The costs covered by sponsors include travel costs such as airfare and lodging.

Is Enzyme Replacement Therapy available for GM1?

Not yet. It is a major area of research, but it is not currently available in a clinical trial or as an approved treatment.

Is there a cure for GM1 today?

No approved cure exists as of 2026.

References

  1. Regier DS, Tifft CJ, Rothermel CE. GLB1-related disorders. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2013 Oct 17 [updated 2021 Apr 22]. https://www.ncbi.nlm.nih.gov/books/NBK164500/ Accessed August 13, 2026.
  2. D’Souza P, Farmer C, Johnston JM, et al. GM1 gangliosidosis type II: results of a 10-year prospective study. Genet Med. 2024;26(7):101144. doi:10.1016/j.gim.2024.101144. PMID 38641994. Free full text at PMC11348282.
  3. Héron B, Batzios S, Mengel E, et al. A natural history study of pediatric patients with early onset of GM1 gangliosidosis, GM2 gangliosidoses, or Gaucher disease type 2 (RETRIEVE). Orphanet J Rare Dis. 2024;19(1):459. doi:10.1186/s13023-024-03409-1. PMID 39639297. Free full text at PMC11619657.
  4. Laur D, Pichard S, Bekri S, et al. Natural history of GM1 gangliosidosis—Retrospective cohort study of 61 French patients from 1998 to 2019. J Inherit Metab Dis. 2023;46(5):972-981. doi:10.1002/jimd.12646. PMID 37381921.
  5. Jarnes Utz JR, Kim S, King K, et al. Infantile gangliosidoses: mapping a timeline of clinical changes. Mol Genet Metab. 2017;121(2):170-179. doi:10.1016/j.ymgme.2017.04.011. PMID 28476546. Free full text at PMC5727905.
  6. University of Minnesota. Synergistic enteral regimen for treatment of the gangliosidoses (Syner-G). Interventions: miglustat and ketogenic diet. ClinicalTrials.gov identifier NCT02030015. https://clinicaltrials.gov/study/NCT02030015 Terminated, status checked August 13, 2026.
  7. University of Pennsylvania (collaborator: Passage Bio, Inc.). Natural history study of infantile and juvenile GM1 gangliosidosis (GM1) patients. ClinicalTrials.gov identifier NCT04041102. https://clinicaltrials.gov/study/NCT04041102 Completed, status checked August 14, 2026.
  8. Gemma Biotherapeutics. Phase 1/2 open-label, multicenter study to assess the safety, tolerability and efficacy of a single dose of PBGM01 delivered into the cisterna magna of pediatric type 1 (early onset) and type 2a (late onset) infantile GM1 gangliosidosis. ClinicalTrials.gov identifier NCT04713475. https://clinicaltrials.gov/study/NCT04713475 Active, not recruiting, status checked August 13, 2026.
  9. University of Minnesota (collaborators: Rare Diseases Clinical Research Network; Lysosomal Disease Network). A natural history study of the gangliosidoses. ClinicalTrials.gov identifier NCT00668187. https://clinicaltrials.gov/study/NCT00668187 Recruiting, status checked August 14, 2026.
  10. National Human Genome Research Institute (NHGRI). Natural history of glycosphingolipid storage disorders and glycoprotein disorders. ClinicalTrials.gov identifier NCT00029965. https://clinicaltrials.gov/study/NCT00029965 Recruiting, status checked August 14, 2026.
  11. National Human Genome Research Institute (collaborator: Sio Gene Therapies). A phase 1/2 study of intravenous gene transfer with an AAV9 vector expressing human beta-galactosidase in type I and type II GM1 gangliosidosis. ClinicalTrials.gov identifier NCT03952637. https://clinicaltrials.gov/study/NCT03952637 Recruiting, status checked August 13, 2026.
  12. Idorsia Pharmaceuticals Ltd. Natural history study for pediatric patients with early onset of either GM1 gangliosidosis, GM2 gangliosidosis, or Gaucher disease type 2. ClinicalTrials.gov identifier NCT04470713. https://clinicaltrials.gov/study/NCT04470713 Completed, status checked August 14, 2026.
  13. Lysogene. A safety and efficacy study of LYS-GM101 gene therapy in patients with GM1 gangliosidosis. ClinicalTrials.gov identifier NCT04273269. https://clinicaltrials.gov/study/NCT04273269 Terminated, closed due to the sponsor’s cessation of activities and not due to safety reasons, status checked August 14, 2026.
  14. Lewis CJ, D’Souza P, Johnston JM, et al. AAV9 gene therapy in type II GM1 gangliosidosis: a phase 1-2 trial. N Engl J Med. 2026;394(12):1184-1194. doi:10.1056/NEJMoa2510935. PMID 41665410. Free full text at PMC13215599.
  15. Mackenzie T; University of California, San Francisco. A phase I study of prenatal intravenous gene transfer with an AAV9 vector expressing human beta-galactosidase in type I and type II GM1 gangliosidosis. ClinicalTrials.gov identifier NCT07479953. https://clinicaltrials.gov/study/NCT07479953 Not yet recruiting, status checked August 13, 2026.
  16. Tifft CJ, Batsu I, Giugliani R, et al. Venglustat in GM2 gangliosidoses and related disorders: results of the AMETHIST randomized controlled and basket trials. Genet Med. 2026;28(1):101615. doi:10.1016/j.gim.2025.101615. PMID 41108138.
  17. Genzyme, a Sanofi Company. A multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, and safety of venglustat in late-onset GM2 gangliosidosis (AMETHIST). ClinicalTrials.gov identifier NCT04221451. https://clinicaltrials.gov/study/NCT04221451 Terminated, discontinued based on the absence of positive trends on clinical endpoints, status checked August 14, 2026.
  18. Sanofi. Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance [press release]. Paris: Sanofi; April 25, 2024:7. https://ml-eu.globenewswire.com/Resource/Download/ca345f70-58d6-4aa7-a4b1-8b6b43551051 Accessed August 13, 2026.
  19. Sanofi. Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease type 3. ClinicalTrials.gov identifier NCT05222906. https://clinicaltrials.gov/study/NCT05222906 Active, not recruiting, status checked August 13, 2026.
  20. Azafaros B.V. A study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis. ClinicalTrials.gov identifier NCT07082543. https://clinicaltrials.gov/study/NCT07082543 Active, not recruiting, status checked August 13, 2026.

Support Our Mission to Cure GM1

  • Help fund critical research for a GM1 cure.
  • Support families affected by GM1.
  • Accelerate clinical trials for life-saving treatments.
Donate Now

Published February 27, 2026. Last updated: August 14, 2026.